Evidence map›Paper›PMID 34099897›Full record

ReviewCell death and differentiation2021

Molecular mechanisms of cell death in neurological diseases.

Diane Moujalled, Andreas Strasser, Jeffrey R Liddell

Open access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cell death and differentiation, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 425 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
425citing papers in PubMed, 5 pooled it
53.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

425 citing papers in PubMed, 5 syntheses or guidelines pooled it, 720 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Review
  8. Molecular and cellular mechanisms of lead-induced neurotoxicity: comparative insights from rodent and zebrafish models.Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine · 2026
    Review
  9. Article
  10. The emerging roles of disulfidptosis in cancer.Apoptosis : an international journal on programmed cell death · 2026
    Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

365 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Diane MoujalledThe Walter and Eliza Hall Institute, Parkville, VIC, Australia. dmoujalled@wehi.edu.au.ORCID http://orcid.org/0000-0002-6405-2788
Andreas StrasserThe Walter and Eliza Hall Institute, Parkville, VIC, Australia. strasser@wehi.edu.au.ORCID http://orcid.org/0000-0002-5020-4891
Jeffrey R LiddellDepartment of Biochemistry and Pharmacology, The University of Melbourne, Parkville, VIC, Australia.ORCID http://orcid.org/0000-0002-0798-5338
The University of Melbourne · AU

Funding

Department of Health | National Health and Medical Research Council (NHMRC) 1020363Wellcome Trust 101671
6 · The paper itself

Abstract

Tightly orchestrated programmed cell death (PCD) signalling events occur during normal neuronal development in a spatially and temporally restricted manner to establish the neural architecture and shaping the CNS. Abnormalities in PCD signalling cascades, such as apoptosis, necroptosis, pyroptosis, ferroptosis, and cell death associated with autophagy as well as in unprogrammed necrosis can be observed in the pathogenesis of various neurological diseases. These cell deaths can be activated in response to various forms of cellular stress (exerted by intracellular or extracellular stimuli) and inflammatory processes. Aberrant activation of PCD pathways is a common feature in neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS), Alzheimer's disease, Parkinson's disease, and Huntington's disease, resulting in unwanted loss of neuronal cells and function. Conversely, inactivation of PCD is thought to contribute to the development of brain cancers and to impact their response to therapy. For many neurodegenerative diseases and brain cancers current treatment strategies have only modest effect, engendering the need for investigations into the origins of these diseases. With many diseases of the brain displaying aberrations in PCD pathways, it appears that agents that can either inhibit or induce PCD may be critical components of future therapeutic strategies. The development of such therapies will have to be guided by preclinical studies in animal models that faithfully mimic the human disease. In this review, we briefly describe PCD and unprogrammed cell death processes and the roles they play in contributing to neurodegenerative diseases or tumorigenesis in the brain. We also discuss the interplay between distinct cell death signalling cascades and disease pathogenesis and describe pharmacological agents targeting key players in the cell death signalling pathways that have progressed through to clinical trials.

Indexed as

AutophagyRegulated Cell DeathAnimalsBrainHumansNeurodegenerative DiseasesNeuronsSignal Transduction

Identifiers

PMID34099897
PMCPMC8257776
OpenAlexW3171124897

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.